Brusatol inhibits malignant phenotypes and lipid metabolism of osteosarcoma cells by regulating PI3K/AKT and MAPK pathways
- 12 February 2025
- journal article
- Published by Elsevier in Phytomedicine
- Vol. 139, 156464
Abstract
No abstract availableKeywords
Funding Information
- Fujian Institute of Innovation, Chinese Academy of Sciences (2023CXA020)
- Fujian Medical University
- Natural Science Foundation of Fujian Province (2023J011778)
- National Natural Science Foundation of China (82371375)
This publication has 38 references indexed in Scilit:
- Targeting proteostasis network in osteoporosis: Pathological mechanisms and therapeutic implicationsAgeing Research Reviews, 2023
- The role of lipids in cancer progression and metastasisCell Metabolism, 2022
- Osteosarcoma: A Surveillance, Epidemiology, and End Results program‐based analysis from 1975 to 2017Cancer, 2022
- Preoperative prognostic nutritional index and systemic immune‐inflammation index predict survival outcomes in osteosarcoma: A comparison between young and elderly patientsJournal of Surgical Oncology, 2021
- International trends in incidence of osteosarcoma (1988‐2012)International Journal of Cancer, 2021
- Lipid metabolism in cancer: New perspectives and emerging mechanismsDevelopmental Cell, 2021
- Anticancer effects of brusatol in nasopharyngeal carcinoma through suppression of the Akt/mTOR signaling pathwayCancer Chemotherapy and Pharmacology, 2020
- Comprehensive anti-tumor effect of Brusatol through inhibition of cell viability and promotion of apoptosis caused by autophagy via the PI3K/Akt/mTOR pathway in hepatocellular carcinomaBiomedicine & Pharmacotherapy, 2018
- Cellular Fatty Acid Metabolism and CancerCell Metabolism, 2013
- Osteosarcoma incidence and survival rates from 1973 to 2004Cancer, 2009